Biohit Oyj Past Earnings Performance

Past criteria checks 4/6

Biohit Oyj has been growing earnings at an average annual rate of 49.2%, while the Medical Equipment industry saw earnings growing at 5% annually. Revenues have been growing at an average rate of 6% per year. Biohit Oyj's return on equity is 19.6%, and it has net margins of 14.2%.

Key information

49.2%

Earnings growth rate

49.3%

EPS growth rate

Medical Equipment Industry Growth28.7%
Revenue growth rate6.0%
Return on equity19.6%
Net Margin14.2%
Next Earnings Update07 Aug 2024

Recent past performance updates

Biohit Oyj's (HEL:BIOBV) Solid Profits Have Weak Fundamentals

Feb 22
Biohit Oyj's (HEL:BIOBV) Solid Profits Have Weak Fundamentals

Recent updates

Biohit Oyj's (HEL:BIOBV) Solid Profits Have Weak Fundamentals

Feb 22
Biohit Oyj's (HEL:BIOBV) Solid Profits Have Weak Fundamentals

Biohit Oyj Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 17
Biohit Oyj Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Companies Like Biohit Oyj (HEL:BIOBV) Are In A Position To Invest In Growth

Aug 04
Companies Like Biohit Oyj (HEL:BIOBV) Are In A Position To Invest In Growth

Companies Like Biohit Oyj (HEL:BIOBV) Are In A Position To Invest In Growth

Feb 09
Companies Like Biohit Oyj (HEL:BIOBV) Are In A Position To Invest In Growth

Biohit Oyj (HEL:BIOBV) Is In A Strong Position To Grow Its Business

Aug 11
Biohit Oyj (HEL:BIOBV) Is In A Strong Position To Grow Its Business

Biohit Oyj (HEL:BIOBV) Is In A Strong Position To Grow Its Business

Apr 13
Biohit Oyj (HEL:BIOBV) Is In A Strong Position To Grow Its Business

We Think Biohit Oyj (HEL:BIOBV) Can Afford To Drive Business Growth

Dec 28
We Think Biohit Oyj (HEL:BIOBV) Can Afford To Drive Business Growth

Revenue & Expenses Breakdown
Beta

How Biohit Oyj makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

HLSE:BIOBV Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2313240
30 Sep 2312140
30 Jun 2311140
31 Mar 2311140
31 Dec 2211140
30 Sep 2211140
30 Jun 2211140
31 Mar 2210040
31 Dec 219-130
30 Sep 219-230
30 Jun 218-230
31 Mar 218-330
31 Dec 207-330
30 Sep 208-330
30 Jun 208-330
31 Mar 209-230
31 Dec 1910-130
30 Sep 1910-230
30 Jun 1910-230
31 Mar 1910-230
31 Dec 1810-230
30 Sep 1810-230
30 Jun 1810-230
31 Mar 189230
31 Dec 179630
30 Sep 17964-1
30 Jun 17864-1
31 Mar 17814-1
31 Dec 168-350
30 Sep 167-451
30 Jun 166-452
31 Mar 167-352
31 Dec 156-352
30 Sep 156-352
30 Jun 156-452
31 Mar 155-452
31 Dec 144-452
30 Sep 144-552
30 Jun 144-562
31 Mar 144-671
31 Dec 133-671
30 Sep 133-561
30 Jun 133-561

Quality Earnings: BIOBV has a high level of non-cash earnings.

Growing Profit Margin: BIOBV's current net profit margins (14.2%) are higher than last year (5.5%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: BIOBV has become profitable over the past 5 years, growing earnings by 49.2% per year.

Accelerating Growth: BIOBV's earnings growth over the past year (208%) exceeds its 5-year average (49.2% per year).

Earnings vs Industry: BIOBV earnings growth over the past year (208%) exceeded the Medical Equipment industry 5.2%.


Return on Equity

High ROE: BIOBV's Return on Equity (19.6%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.